TheraCell’s TheraFuse™ Oxygenation technology utilizes a proprietary formulation of high oxygen capacity materials saturated with molecular oxygenation. The use of TheraCells oxygenating formulation as a component of an orthopedic implant is novel and TheraCell has been granted multiple patents. The technology allows healing to be effected even before the body has developed vascularization of a site, and thus acts as a powerful stimulus to the healing process. The use of this proprietary technology provides a cost effective alternative to the use of the more expensive morphogenic protein products that have recently become less popular due to safety concerns. In-vivo proof of concept has been demonstrated in multiple pre-clinical models including rat subcutaneous, intramuscular, and PLF models, and the technology is now being further developed for commercialization in conjunction with our DBF™ Fiber Matrix Technology™.